Chevy Chase, MD, November 5, 2003-- New research published this month in the journal Endocrinology highlights a possible safe, future treatment for postmenopausal women. The research, which was conducted by doctors at Laval University in Quebec, Canada, found that EM-652, a selective estrogen receptor modulator (SERM) given in association with an estrogen, may be effective at controlling hot flashes and preventing breast, uterine and ovarian cancer as well as osteoporosis in postmenopausal women.
Additionally, the combination shows promise in potentially helping with brain function and preventing Alzheimer's disease with no risk or negative effect.
Over the past year, millions of women have become afraid and confused about the risks and benefits of hormone replacement therapy following the results of the Women's Health Initiative Study (WHI), which found that women on the combination replacement estrogen and progestin have an increased risk (26 percent) of developing breast cancer. In light of these findings, the medical community has worked to determine the best way to treat the symptoms and risks of menopause, while researchers search for alternative therapies for the millions of women who used combination hormones to treat their menopausal symptoms, such as hot flashes. Dr. Fernand Labrie and his colleagues in Quebec, Canada have now demonstrated that the next generation of menopausal therapy may lie in a combination of SERMs and estrogen, with the SERM preventing the potential risk of breast cancer caused by the estrogen.
Through three separate studies on rats, Dr. Labrie and his team sought to validate the promise of EM-652 as a postmenopausal treatment. The researchers treated different groups of rats with EM-652 and estrogen and measured the impact on the mammary gland and uterus. One study examined the effects of 17beta-estradiol, an estrogen and EM-652 alone and in combination.
The findings showed that when adminPage: 1 2 Related medicine news :1
Contact: Marisa Lavine
The Endocrine Society & The Hormone Foundation
. First head-to-head study to compare lidoderm patch and Celebrex in treating pain2
. UMaine study looks at infants and chronic nighttime crying3
. Chronic pain treatments more effective when taken together, new study shows4
. UNC study: Most N.C. family practitioners engage in unrecognized community service5
. New study in Nature demonstrates protection against cell death during heart attack6
. UCSF study offers insight into human circadian rhythms7
. International breast cancer prevention study launches in the United States and Canada8
. UW study shows blacks and Latinos are more satisfied with physicians of the same race9
. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study10
. Advertising by academic medical centers may risk eroding public trust, says study11
. Fat may promote inflammation, new study suggests